Fsole

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3952212/publications.pdf

Version: 2024-02-01

223 papers	9,336 citations	81900 39 h-index	46799 89 g-index
227 all docs	227 docs citations	227 times ranked	9537 citing authors

#	Article	IF	Citations
1	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood, 2012, 120, 2454-2465.	1.4	2,458
2	New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. Journal of Clinical Oncology, 2012, 30, 820-829.	1.6	584
3	Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. Cancer Research, 2010, 70, 1408-1418.	0.9	429
4	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
5	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
6	Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica, 2011, 96, 375-383.	3.5	226
7	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood, 2010, 116, 1479-1488.	1.4	174
8	Guidance for laboratories performing molecular pathology for cancer patients. Journal of Clinical Pathology, 2014, 67, 923-931.	2.0	169
9	Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood, 2002, 99, 1299-1304.	1.4	158
10	Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS. Cancer Cell, 2014, 26, 509-520.	16.8	158
11	Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: Primary breakpoints and clinical correlations. Genes Chromosomes and Cancer, 1997, 18, 84-93.	2.8	150
12	Time-dependent changes in mortality and transformation risk in MDS. Blood, 2016, 128, 902-910.	1.4	140
13	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2021, 39, 1223-1233.	1.6	127
14	Progression to Large B-Cell Lymphoma in Splenic Marginal Zone Lymphoma. American Journal of Surgical Pathology, 2001, 25, 1268-1276.	3.7	126
15	Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood, 2001, 98, 2837-2844.	1.4	125
16	Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood, 2003, 101, 4042-4046.	1.4	121
17	Gastrointestinal Involvement in Mantle Cell Lymphoma: A Prospective Clinic, Endoscopic, and Pathologic Study. American Journal of Surgical Pathology, 2006, 30, 1274-1280.	3.7	121
18	MYC-containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene. Human Molecular Genetics, 2006, 15, 933-942.	2.9	116

#	ARTICLE	IF	CITATIONS
19	Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. Blood, 2020, 136, 1851-1862.	1.4	112
20	CD133 expression in circulating tumor cells from breast cancer patients: Potential role in resistance to chemotherapy. International Journal of Cancer, 2013, 133, 2398-2407.	5.1	92
21	Biomarkers characterization of circulating tumour cells in breast cancer patients. Breast Cancer Research, 2012, 14, R71.	5.0	82
22	MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell Lymphomas. Cancer Research, 2009, 69, 7071-7078.	0.9	78
23	Epidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomas. Experimental Dermatology, 2010, 19, 151-153.	2.9	77
24	Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistry. Breast Cancer Research, 2005, 7, R267-73.	5.0	76
25	Clinical Utility of a Multiprobe FISH Assay in Voided Urine Specimens for the Detection of Bladder Cancer and its Recurrences, Compared with Urinary Cytology. European Urology, 2002, 42, 547-552.	1.9	74
26	Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. British Journal of Haematology, 2013, 162, 74-86.	2.5	73
27	Type IMOZ/CBP (MYST3/CREBBP)is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes and Cancer, 2004, 40, 140-145.	2.8	72
28	Oligonucleotide Array-CGH Identifies Genomic Subgroups and Prognostic Markers for Tumor Stage Mycosis Fungoides. Journal of Investigative Dermatology, 2010, 130, 1126-1135.	0.7	71
29	Molecular diagnosis of dermatofibrosarcoma protuberans: A comparison between reverse transcriptaseâ€polymerase chain reaction and fluorescence in situ hybridization methodologies. Genes Chromosomes and Cancer, 2011, 50, 510-517.	2.8	69
30	Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes and Cancer, 2010, 49, 439-451.	2.8	68
31	Complex, Not Monosomal, Karyotype Is the Cytogenetic Marker of Poorest Prognosis in Patients With Primary Myelodysplastic Syndrome. Journal of Clinical Oncology, 2013, 31, 916-922.	1.6	65
32	Frequent involvement of chromosomes 1, 3, 7 and 8 in splenic marginal zone Bâ€cell lymphoma. British Journal of Haematology, 1997, 98, 446-449.	2.5	56
33	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood, 2016, 128, 2096-2097.	1.4	46
34	Lymphomatoid Papulosis Associated with Mycosis Fungoides: Clinicopathological and Molecular Studies of 12 Cases. Acta Dermato-Venereologica, 2004, 84, 463-468.	1.3	44
35	Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing. Genes Chromosomes and Cancer, 2013, 52, 1167-1177.	2.8	44
36	Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry. Clinical Cancer Research, 2014, 20, 1007-1019.	7.0	44

#	ARTICLE	IF	CITATIONS
37	Identification of t(17;22)(q22;q13) (COL1A1/PDGFB) in dermatofibrosarcoma protuberans by fluorescence in situ hybridization in paraffin-embedded tissue microarrays. Human Pathology, 2011, 42, 176-184.	2.0	43
38	Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer, 2012, 118, 127-133.	4.1	43
39	Prognostic significance of copy number alterations in adolescent and adult patients with precursor <scp>B</scp> acute lymphoblastic leukemia enrolled in <scp>PETHEMA</scp> protocols. Cancer, 2015, 121, 3809-3817.	4.1	43
40	The MYC oncogene in breast cancer progression: from benign epithelium to invasive carcinoma. Cancer Genetics and Cytogenetics, 2006, 165, 151-156.	1.0	42
41	Clonal proliferation of cyclin D1â€“positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma?. Human Pathology, 2005, 36, 1232-1237.	2.0	41
42	Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. Blood, 2018, 132, 2309-2313.	1.4	38
43	FISH is better than BIOMED-2 PCR to detect IgH/BCL2 translocation in follicular lymphoma at diagnosis using paraffin-embedded tissue sections. Leukemia Research, 2008, 32, 737-742.	0.8	37
44	Clinical relevance of clonal hematopoiesis in persons aged â‰¥80 years. Blood, 2021, 138, 2093-2105.	1.4	37
45	Aberrant nuclear BCL10 expression and lack of t(11;18)(q21;q21) in primary cutaneous marginal zone B-cell lymphoma. Human Pathology, 2006, 37, 867-873.	2.0	36
46	Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. Haematologica, 2008, 93, 1001-1008.	3.5	36
47	TERT gene amplification is associated with poor outcome in acral lentiginous melanoma. Journal of the American Academy of Dermatology, 2014, 71, 839-841.	1.2	35
48	Study of Regulatory T-Cells in Patients with Gastric Malt Lymphoma: Influence on Treatment Response and Outcome. PLoS ONE, 2012, 7, e51681.	2.5	35
49	HLA-G positive trophoblastic cells in transcervical samples and their isolation and analysis by laser microdissection and QF-PCR. Prenatal Diagnosis, 2003, 23, 34-39.	2.3	32
50	Identification of Temporal and Region-Specific Myocardial Gene Expression Patterns in Response to Infarction in Swine. PLoS ONE, 2013, 8, e54785.	2.5	32
51	Translocation (11;14)(q13;q32) and Preferential Involvement of Chromosomes 1, 2, 9, 13, and 17 in Mantle Cell Lymphoma. Cancer Genetics and Cytogenetics, 1999, 111, 92-98.	1.0	31
52	Genetic diagnosis by comparative genomic hybridization in adult de novo acute myelocytic leukemia. Cancer Genetics and Cytogenetics, 2004, 153, 16-25.	1.0	29
53	3q26 (hTERC) gain studied by fluorescence in situ hybridization as a persistence-progression indicator in low-grade squamous intraepithelial lesion cases. Human Pathology, 2009, 40, 1474-1478.	2.0	29
54	Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood, 2022, 139, 2273-2284.	1.4	29

#	ARTICLE	IF	CITATIONS
55	Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes and Cancer, 2008, 47, 1086-1097.	2.8	28
56	TERT and AURKA Gene Copy Number Gains Enhance the Detection of Acral Lentiginous Melanomas by Fluorescence in Situ Hybridization. Journal of Molecular Diagnostics, 2014, 16, 198-206.	2.8	28
57	De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19. Genes Chromosomes and Cancer, 2003, 36, 406-412.	2.8	27
58	Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features. Oncotarget, 2016, 7, 57021-57035.	1.8	26
59	Prognostic value of trisomy 8 as a single anomaly and the influence of additional cytogenetic aberrations in primary myelodysplastic syndromes. British Journal of Haematology, 2012, 159, 311-321.	2.5	25
60	Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2020, 188, 605-622.	2.5	25
61	Genomic Abnormalities Acquired in the Blastic Transformation of Splenic Marginal Zone B-cell Lymphoma. Leukemia and Lymphoma, 2003, 44, 459-464.	1.3	24
62	Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. Oncogene, 2004, 23, 8941-8949.	5.9	23
63	Does monosomy 5 really exist in myelodysplastic syndromes and acute myeloid leukemia?. Leukemia Research, 2010, 34, 1242-1245.	0.8	23
64	FISH and immunohistochemical status of the hepatocyte growth factor receptor (c-Met) in 184 invasive breast tumors. Breast Cancer Research, 2009, 11, 402.	5.0	22
65	Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?. Leukemia Research, 2012, 36, 832-840.	0.8	21
66	Copy number profiling of adult relapsed Bâ€cell precursor acute lymphoblastic leukemia reveals potential leukemia progression mechanisms. Genes Chromosomes and Cancer, 2017, 56, 810-820.	2.8	21
67	Cytogenetic studies in acute nonlymphocytic leukemia. Cancer Genetics and Cytogenetics, 1992, 60, 117-124.	1.0	20
68	New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY). Leukemia Research, 2008, 32, 727-736.	0.8	20
69	Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group. Haematologica, 2015, 100, 205-213.	3.5	20
70	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research, 2018, 73, 51-57.	0.8	20
71	CD34+CD19â^'CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. Blood, 2022, 140, 38-44.	1.4	20
72	A new chromosomal anomaly associated with mature B-cell chronic lymphoproliferative disorders: del(7)(q32). Cancer Genetics and Cytogenetics, 1993, 65, 170-172.	1.0	19

#	ARTICLE	IF	CITATIONS
73	Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop. Leukemia Research, 2012, 36, 264-270.	0.8	19
74	Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?. PLoS ONE, 2015, 10, e0129375.	2.5	19
75	Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia. Cancer Genetics and Cytogenetics, 2004, 148, 71-76.	1.0	18
76	Endogenous erythroid and megakaryocytic circulating progenitors, HUMARA clonality assay, and PRV-1 expression are useful tools for diagnosis of polycythemia vera and essential thrombocythemia. Blood, 2004, 103, 2427-2428.	1.4	18
77	Genomic arrays in chronic lymphocytic leukemia routine clinical practice: are we ready to substitute conventional cytogenetics and fluorescencein situhybridization techniques?. Leukemia and Lymphoma, 2013, 54, 986-995.	1.3	18
78	Impact of <scp>SNP</scp> array karyotyping on the diagnosis and the outcome of chronic myelomonocytic leukemia with low risk cytogenetic features or no metaphases. American Journal of Hematology, 2016, 91, 185-192.	4.1	18
79	Acute lymphoblastic leukemia with t(4;11) in a patient previously exposed to a carcinogen. Cancer Genetics and Cytogenetics, 1990, 49, 133-136.	1.0	17
80	Comparative genomic hybridization analysis of cutaneous large B-cell lymphomas. Experimental Dermatology, 2005, 14, 883-890.	2.9	17
81	Diagnostic and prognostic contribution of targeted NGS in patients with tripleâ€negative myeloproliferative neoplasms. American Journal of Hematology, 2019, 94, E264-E267.	4.1	17
82	Cytogenetic Findings in Five Patients with Hairy Cell Leukemia. Cancer Genetics and Cytogenetics, 1999, 110, 41-43.	1.0	16
83	Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 141, 114-119.	1.0	16
84	Application of FISH 7q in MDS patients without monosomy 7 or 7q deletion by conventional G-banding cytogenetics: Does â˜7/7qâ˜ detection by FISH have prognostic value?. Leukemia Research, 2013, 37, 416-421.	0.8	16
85	CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma. Histology and Histopathology, 2011, 26, 71-7.	0.7	16
86	FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type. Histology and Histopathology, 2011, 26, 213-21.	0.7	16
87	Heterogeneity of structural abnormalities in the 7q31.3â¼q34 region in myeloid malignancies. Cancer Genetics and Cytogenetics, 2004, 150, 136-143.	1.0	15
88	Does Polysomy of Chromosome 17 Have a Role in ERBB2 and Topoisomerase IIα Expression?. Tumor Biology, 2007, 28, 221-228.	1.8	15
89	Small supernumerary marker chromosome causing partial trisomy 6p in a child with craniosynostosis. American Journal of Medical Genetics, Part A, 2007, 143A, 1108-1113.	1.2	15
90	Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype. Genes Chromosomes and Cancer, 2013, 52, 753-763.	2.8	15

#	Article	IF	Citations
91	Is fluorescence in situ hybridization a useful method in diagnosis of polycythemia vera patients?. Cancer Genetics and Cytogenetics, 2004, 151, 139-145.	1.0	14
92	Absence of CHEK2 mutations in Spanish families with hereditary breast cancer. Cancer Genetics and Cytogenetics, 2005, 161, 93-95.	1.0	14
93	Correlation between histologic findings and cytogenetic abnormalities in bladder carcinoma: A FISH study. Urology, 2005, 65, 913-918.	1.0	14
94	Primary Cutaneous CD30+ Anaplastic Large-Cell Lymphomas Show a Heterogeneous Genomic Profile: An Oligonucleotide ArrayCGH Approach. Journal of Investigative Dermatology, 2011, 131, 269-271.	0.7	14
95	Computational drug treatment simulations on projections of dysregulated protein networks derived from the myelodysplastic mutanome match clinical response in patients. Leukemia Research, 2017, 52, 1-7.	0.8	14
96	DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features. Epigenetics, 2018, 13, 8-18.	2.7	14
97	Impact of somatic mutations in myelodysplastic patients with isolated partial or total loss of chromosome 7. Leukemia, 2020, 34, 2441-2450.	7.2	14
98	TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes. Oncotarget, 2015, 6, 34437-34445.	1.8	14
99	Isochromosome 14q in myeloid dysplastic disorder. Cancer Genetics and Cytogenetics, 1991, 54, 133-134.	1.0	13
100	Biallelic losses of 13q do not confer a poorer outcome in chronic lymphocytic leukaemia: analysis of 627 patients with isolated 13q deletion. British Journal of Haematology, 2013, 163, 47-54.	2.5	13
101	Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): Clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3. Hematology, 2015, 20, 435-441.	1.5	13
102	Cytogenetic Abnormalities in Three Patients with B-Cell Prolymphocytic Leukemia. Cancer Genetics and Cytogenetics, 1998, 103, 43-45.	1.0	12
103	CD5 negative and CD5 positive splenic marginal B-cell lymphomas have differential cytogenetic patterns. Leukemia Research, 2005, 29, 981-982.	0.8	12
104	Characterization of HER1 (c-erbB1) Status in Locally Advanced Breast Cancer Using Fluorescence in situ Hybridization and Immunohistochemistry. Tumor Biology, 2005, 26, 25-30.	1.8	12
105	Cytogenetic studies in five patients with SÃ©zary syndrome. Cancer Genetics and Cytogenetics, 1994, 75, 130-132.	1.0	11
106	A new case of t(14;19) (q32;q13) in a patient with follicular lymphoma in leukemic phase. Cancer Genetics and Cytogenetics, 1994, 75, 72-73.	1.0	11
107	Two New Cases of Near-Tetraploidy in Adult Acute Myeloid Leukemia. Cancer Genetics and Cytogenetics, 1998, 102, 131-134.	1.0	11
108	Comparative Analysis of TCR-Î³ Gene Rearrangements by Genescan and Polyacrylamide Gel-electrophoresis in Cutaneous T-cell Lymphoma. Acta Dermato-Venereologica, 2003, 84, 6-11.	1.3	11

#	ARTICLE	IF	CITATIONS
109	Insertion (8;11) in a renal oncocytoma with multifocal transformation to chromophobe renal cell carcinoma. Cancer Genetics and Cytogenetics, 2005, 163, 160-163.	1.0	11
110	Blast cells with nuclear extrusions in the form of micronuclei are associated with MYC amplification in acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2008, 185, 32-36.	1.0	11
111	Cryptic IGH/BCL2 rearrangements with variant FISH patterns in follicular lymphoma. Leukemia Research, 2011, 35, 256-259.	0.8	11
112	Clinical impact of the clone size in MDS cases with monosomy 7 or 7q deletion, trisomy 8, 20q deletion and loss of Y chromosome. Leukemia Research, 2011, 35, 834-836.	0.8	11
113	Are ER+PR+ and ER+PRâ˜' breast tumors genetically different? A CGH array study. Cancer Genetics, 2012, 205, 138-146.	0.4	11
114	Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome. Leukemia Research, 2013, 37, 769-776.	0.8	11
115	Paraffin Treasures: Do They Last Forever?. Biopreservation and Biobanking, 2014, 12, 281-283.	1.0	11
116	Correlation of myelodysplastic syndromes with i(17)(q10) and <scp>TP</scp>53 and <scp>SETBP</scp>1 mutations. British Journal of Haematology, 2015, 171, 137-141.	2.5	11
117	Targeted deep sequencing of CD34+ cells from peripheral blood can reproduce bone marrow molecular profile in myelodysplastic syndromes. American Journal of Hematology, 2018, 93, E152-E154.	4.1	11
118	Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML. Scientific Reports, 2018, 8, 13883.	3.3	11
119	Adverse prognostic impact of complex karyotype (â‰¥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leukemia Research, 2021, 109, 106612.	0.8	11
120	Contribution of cytogenetics and in situ hybridization to the study of monoclonal gammopathies of undetermined significance. Cancer Genetics and Cytogenetics, 2002, 132, 25-29.	1.0	10
121	CKS1B amplification is a frequent event in cutaneous squamous cell carcinoma with aggressive clinical behaviour. Genes Chromosomes and Cancer, 2010, 49, 1054-1061.	2.8	10
122	Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia. Genes Chromosomes and Cancer, 2017, 56, 243-252.	2.8	10
123	Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms. Cancers, 2021, 13, 2120.	3.7	10
124	Coexistence of tetrasomy 8 and trisomy 8 in a case with myeloid metaplasia with myelofibrosis. Cancer Genetics and Cytogenetics, 1997, 94, 147-150.	1.0	9
125	TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study. Haematologica, 2010, 95, 1798-1800.	3.5	9
126	Absence of TCR loci chromosomal translocations in cutaneous T-cell lymphomas. Cancer Genetics, 2011, 204, 405-409.	0.4	9

#	ARTICLE	IF	CITATIONS
127	Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): A population-based study, 1993â€“2007. Leukemia Research, 2012, 36, 1262-1266.	0.8	9
128	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leukemia Research, 2017, 63, 85-89.	0.8	9
129	Report of 46,XX/46,XY/47,XXY/48,XXYY mosaicism in an adult phenotypic male. American Journal of Medical Genetics Part A, 2002, 111, 215-217.	2.4	8
130	Analysis of T-Cell Receptor Î³ Gene Rearrangements by PCR-Genescan and PCR-Polyacrylamide Gel Electrophoresis in Early-Stage Mycosis fungoides/Large-Plaque Parapsoriasis. Dermatology, 2003, 207, 418-419.	2.1	8
131	5qâ^' syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide. Leukemia Research, 2013, 37, 1248-1250.	0.8	8
132	Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a <scp>G</scp>erman diagnostic study in comparison with an international control group. Genes Chromosomes and Cancer, 2015, 54, 809-817.	2.8	8
133	Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes. Genes Chromosomes and Cancer, 2019, 58, 689-697.	2.8	8
134	Rare germline variant contributions to myeloid malignancy susceptibility. Leukemia, 2020, 34, 1675-1678.	7.2	8
135	Translocation t(6;14)(p12;q32): a novel cytogenetic abnormality in splenic lymphoma with villous lymphocytes. British Journal of Haematology, 2000, 110, 241-243.	2.5	8
136	G-banding improvement for the MAC method. Cancer Genetics and Cytogenetics, 1991, 51, 41-44.	1.0	7
137	Pentasomy 21 with two isochromosomes 21 in a case of acute myeloid leukemia without maturation. Cancer Genetics and Cytogenetics, 2002, 132, 71-73.	1.0	7
138	Cytogenetic characterization of NCI-H69 and NCI-H69AR small cell lung cancer cell lines by spectral karyotyping. Cancer Genetics and Cytogenetics, 2009, 191, 97-101.	1.0	7
139	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. Genes Chromosomes and Cancer, 2016, 55, 322-327.	2.8	7
140	Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. International Journal of Molecular Sciences, 2018, 19, 3249.	4.1	7
141	Non-del(5q) myelodysplastic syndromesâ€“associated loci detected by SNP-array genome-wide association meta-analysis. Blood Advances, 2019, 3, 3579-3589.	5.2	7
142	Dicentric (17;18) in a Case of Atypical B-Cell Chronic Lymphocytic Leukemia. Cancer Genetics and Cytogenetics, 2000, 121, 194-197.	1.0	6
143	A new case of acute nonlymphocytic leukemia (Frenchâ€“Americanâ€“British subtype M1) with double minutes and c-MYC amplification. Cancer Genetics and Cytogenetics, 2002, 132, 161-164.	1.0	6
144	RxFISH karyotype andMYCamplification in the HT-29 colon adenocarcinoma cell line. Genes Chromosomes and Cancer, 2003, 36, 319-320.	2.8	6

#	ARTICLE	IF	CITATIONS
145	Detection of abnormalities of PRV-1, TPO, and c-MPL genes detected by fluorescence in situ hybridization in essential thrombocythemia. Cancer Genetics and Cytogenetics, 2006, 167, 39-42.	1.0	6
146	Gain of multiple copies of the CBFB gene: a new genetic aberration in a case of granulocytic sarcoma. Cancer Genetics and Cytogenetics, 2007, 179, 62-65.	1.0	6
147	Molecular profiling refines minimal residual diseaseâ€based prognostic assessment in adults with Philadelphia chromosomeâ€negative Bâ€cell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2019, 58, 815-819.	2.8	6
148	The poor prognosis of low hypodiploidy in adults with Bâ€cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. British Journal of Haematology, 2019, 186, 263-268.	2.5	6
149	Trisomy 13 in a patient with a myelodysplastic syndrome. Cancer Genetics and Cytogenetics, 1995, 81, 185.	1.0	5
150	Genetic characterization of the paraimmunoblastic variant of small lymphocytic lymphoma/chronic lymphocytic leukemia: A case report and review of the literature. Human Pathology, 2002, 33, 1145-1148.	2.0	5
151	Additional i(1)(q10) in a primitive neuroectodermal tumor type Merkel cell carcinoma as a primary cytogenetic change. Cancer Genetics and Cytogenetics, 2003, 142, 165-167.	1.0	5
152	Cytogenetic findings in familial B-cell chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 143, 172-173.	1.0	5
153	Amplification of the G allele at SNP rs6983267 in 8q24 amplicons in myeloid malignancies as cause of the lack of MYC overexpression?. Blood Cells, Molecules, and Diseases, 2011, 47, 259-261.	1.4	5
154	Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma. Leukemia Research, 2011, 35, e23-e24.	0.8	5
155	Increased MLL gene rearrangements in amniocytes from fetuses of mothers who smoke. Leukemia Research, 2011, 35, 1066-1069.	0.8	5
156	Translocation t(2;7)(p11.2;q21.2): a rare genetic aberration associated with B-cell lymphoproliferative disorders of marginal-zone origin. Cancer Genetics, 2014, 207, 281-283.	0.4	5
157	Errors in the interpretation of copy number variations due to the use of public databases as a reference. Cancer Genetics, 2014, 207, 164-167.	0.4	5
158	Transcriptomic rationale for synthetic lethalityâ€targeting <scp>ERCC</scp>1 and <scp>CDKN</scp>1A in chronic myelomonocytic leukaemia. British Journal of Haematology, 2018, 182, 373-383.	2.5	5
159	Cytogenetics in the genomic era. Best Practice and Research in Clinical Haematology, 2020, 33, 101196.	1.7	5
160	Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasia. Leukemia and Lymphoma, 2021, 62, 735-738.	1.3	5
161	Analysis of Intratumoral Heterogeneity in Myelodysplastic Syndromes with Isolated del(5q) Using a Single Cell Approach. Cancers, 2021, 13, 841.	3.7	5
162	A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms. Cancers, 2021, 13, 1947.	3.7	5

#	ARTICLE	IF	CITATIONS
163	Analysis of gene status in cervical dysplastic lesions and squamous cell carcinoma using tissue microarrays. Histology and Histopathology, 2009, 24, 821-9.	0.7	5
164	A New Case of Turner Syndrome Associated with Multiple Myeloma. Cancer Genetics and Cytogenetics, 2000, 117, 80-81.	1.0	4
165	Intratumoral heterogeneity of HER2/neu and topoisomerase IIÎ± in breast cancer: a case with clonal monosomy 17. Cancer Genetics and Cytogenetics, 2004, 154, 89-90.	1.0	4
166	Distinct mutational pattern of myelodysplastic syndromes with and without 5qâ€“ treated with lenalidomide. British Journal of Haematology, 2020, 189, e133-e137.	2.5	4
167	New t(11;12)(q12;q11) characterized by RxFISH in a patient with T-cell large granular lymphocyte leukemia. Cancer Genetics and Cytogenetics, 2001, 125, 70-73.	1.0	3
168	ALK status in a primary lung tumour and metachronous metastases. Histopathology, 2012, 60, 843-845.	2.9	3
169	Feasibility of the AML profiler (Skylineâ„¢ Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach. Hematological Oncology, 2017, 35, 778-788.	1.7	3
170	Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance. Genes Chromosomes and Cancer, 2018, 57, 547-556.	2.8	3
171	SF3B1: the lord of the rings in MDS. Blood, 2020, 136, 149-151.	1.4	3
172	Age, Performance Status and Plasma Interleukin-10 Levels At Diagnosis: A Triad for Improving Survival Prediction of Patients with Myelodysplastic Syndromes Already Stratified by IPSS-R. Spanish MDS Group (GESMD). Blood, 2012, 120, 3803-3803.	1.4	3
173	A case of monosomy 20 in an adult acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 1993, 69, 165.	1.0	2
174	Monosomy 15 in chronic myelomonocytic leukemia. Cancer Genetics and Cytogenetics, 2002, 134, 165-167.	1.0	2
175	Genomic rearrangements involving rDNA and centromeric heterochromatin in vulvar epidermoid carcinoma cell line A-431. Cancer Genetics and Cytogenetics, 2003, 143, 50-58.	1.0	2
176	Study of chromosomal abnormalities in 11 cases of cervical dysplasia using comparative genomic hybridization on cotton-lint cervical samples. Cancer Genetics and Cytogenetics, 2006, 164, 61-65.	1.0	2
177	Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?. Leukemia Research, 2007, 31, 1315-1317.	0.8	2
178	Deletion of TET2 gene in an acute myeloid leukemia case with a t(4;15)(q24;q26) characterized by glass needle based chromosome microdissection and oligonucleotide array. Leukemia Research, 2011, 35, e161-e163.	0.8	2
179	Fluorescencein situhybridization ofTP53for the detection of chromosome 17 abnormalities in myelodysplastic syndromes. Leukemia and Lymphoma, 2015, 56, 3183-3188.	1.3	2
180	Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes. Acta Haematologica, 2016, 135, 94-100.	1.4	2

#	Article	IF	Citations
181	Prognostic Impact of Monosomal Karyotype in Patients with Myelodysplastic Syndrome and Abnormal Karyotype. A Report From the Spanish Group of MDS (GESMD). Blood, 2011, 118, 1724-1724.	1.4	2
182	Time Changes In Predictive Power Of MDS Prognostic Scores â€“ Effects On Revised Scores Such As The IPSS-R, Impact Of Age. Blood, 2013, 122, 1544-1544.	1.4	2
183	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 112-112.	1.4	2
184	FOXP1 status in splenic marginal zone lymphoma: a fluorescence in situ hybridization and immunohistochemistry approach. Histology and Histopathology, 2009, 24, 1399-404.	0.7	2
185	Translocation (2;7)(p13;q36) in a case of acute nonlymphocytic leukemia evolving from a myelodysplastic syndrome. Cancer Genetics and Cytogenetics, 1988, 35, 199-204.	1.0	1
186	New chromosomal abnormality. Cancer Genetics and Cytogenetics, 1992, 60, 131-134.	1.0	1
187	Cytogenetic and Fluorescence In Situ Hybridization Studies in Four Cases of Plasma Cell Leukemia. Cancer Genetics and Cytogenetics, 2000, 121, 163-166.	1.0	1
188	Translocation (5;17)(q13;q21) in a case with precursor T-lymphoblastic lymphoma/leukemia. Cancer Genetics and Cytogenetics, 2002, 132, 81-82.	1.0	1
189	Fluorescencein situhybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2015, 56, 242-243.	1.3	1
190	Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance. American Journal of Hematology, 2017, 92, E132-E135.	4.1	1
191	Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. Blood, 2015, 126, 2879-2879.	1.4	1
192	MPO as a Novel Susceptibility Gene in Myeloid Malignancies. Blood, 2019, 134, 5402-5402.	1.4	1
193	Trisomy 4 in a patient with acute myelomonocytic leukemia (M4). Cancer Genetics and Cytogenetics, 1993, 70, 152.	1.0	0
194	Isochromosome +i(3)(q10) in a new case of persistent polyclonal B-cell lymphocytosis (PPBL). European Journal of Haematology, 2000, 64, 344-346.	2.2	0
195	Complex chromosome 8;21 translocation with associated hyperdiploidy in acute myeloid leukemia (FAB-M2). Pediatric Blood and Cancer, 2008, 50, 651-654.	1.5	0
196	Copy Number Alterations in patients with mature B (Burkitt-type) acute lymphoblastic leukaemia treated with specific immunochemotherapy. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S174.	0.4	0
197	Inspecting Targeted Deep Sequencing of Whole Genome Amplified DNA Versus Fresh DNA for Somatic Mutation Detection: A Genetic Study in Myelodysplastic Syndrome Patients. Biopreservation and Biobanking, 2017, 15, 360-365.	1.0	0
198	Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes. Leukemia Research, 2021, 101, 106492.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Cytogenetic and FISH Study of 92 Patients with Splenic Marginal Zone B-Cell Lymphoma (SMZBCL).. Blood, 2004, 104, 699-699.	1.4	0
200	Gastrointestinal Involvement in Mantle Cell Lymphoma (MCL). A Prospective Clinical, Endoscopical, Pathological and Molecular Study.. Blood, 2005, 106, 4665-4665.	1.4	0
201	Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia - Characterization and Prognostic Relevance. Blood, 2010, 116, 4022-4022.	1.4	0
202	Association of MDM2 Gene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome.. Blood, 2012, 120, 2823-2823.	1.4	0
203	Feasibility of the AMLprofilerâ„¢ (Skyline array) in Patient Risk-Stratification in a Multicenter Trial. Comparison with the Standard Approach. Blood, 2012, 120, 4813-4813.	1.4	0
204	Mutational Status of Splenic Marginal Zone Lymphoma Revealed by Whole Exome Sequencing.. Blood, 2012, 120, 2698-2698.	1.4	0
205	Analysis Of Transfusion Dependence Development and Disease Evolution In Patients With MDS and Del(5q) and Without Transfusion Needs At Diagnosis. Blood, 2013, 122, 1542-1542.	1.4	0
206	Prognostic Significance Of Copy Number Alterations In B-Lineage Adult Acute Lymphoblastic Leukemia Patients Enrolled In Risk-Adapted Protocols From The Pethema Group. Blood, 2013, 122, 2556-2556.	1.4	0
207	Whole-Exome Sequencing In Myelodysplastic Syndromes With 5q- and Normal Karyotype. Blood, 2013, 122, 1551-1551.	1.4	0
208	Utility of SNP Arrays in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features or No Metaphases. Blood, 2014, 124, 4659-4659.	1.4	0
209	Genomic Microarray Alterations Add Prognostic Power to the IPSS-R in MDS with Normal Karyotype. Blood, 2014, 124, 3262-3262.	1.4	0
210	Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group. Blood, 2014, 124, 3798-3798.	1.4	0
211	Downregulation of BAP1 in Chronic Myelomonocytic Leukemia: Correlated with a Post-Translational Reduction of BRCA1 Levels and Independent of Promoter Methylation. Blood, 2015, 126, 1648-1648.	1.4	0
212	Molecular Genetic Profiling in Chronic Myelomonocytic Leukemia with Low Risk Cytogenetic Features. Blood, 2015, 126, 2883-2883.	1.4	0
213	Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome. Blood, 2015, 126, 96-96.	1.4	0
214	Abstract 2570: Identification of genetic polymorphisms associated with myelodysplastic syndromes by genome-wide association study. , 2016, , .		0
215	Application of Trusight Myeloid Panel on Whole Genome Amplified DNA in Myelodysplastic Syndrome Patients. Blood, 2016, 128, 5519-5519.	1.4	0
216	Comparison of the Molecular Spectrum of Lenalidomide-Treated Myelodysplastic Syndrome with and without Del(5q). Blood, 2016, 128, 3172-3172.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Genomic Characterization of Paired Diagnosis and Relapse Samples from Adult Patients with B-Cell Precursor Acute Lymphoblastic Leukemia. Blood, 2016, 128, 5281-5281.	1.4	0
218	Landscape of Subclonal Mutations in Myelodysplastic Syndromes (MDS) Allows for a Novel Hierarchy of Clonal Advantage By Combining Germline and Somatic Mutations. Blood, 2016, 128, 957-957.	1.4	0
219	Opposing Pathogenesis of Germline SAMD9/SAMD9L Variants in Adult Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 4351-4351.	1.4	0
220	Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. Blood, 2018, 132, 3103-3103.	1.4	0
221	Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction. Blood, 2018, 132, 4339-4339.	1.4	0
222	Integrated Transcriptomic and Proteomic Analyses of Inflammasome in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Blood, 2019, 134, 2991-2991.	1.4	0
223	Acute Myeloid Leukemia with Isocitrate Dehydrogenases (IDH) 1 and 2 Mutations. a Real-World Study from the European IDH Research Group. Blood, 2020, 136, 30-31.	1.4	0